Clinical significance of CD81 expression by clonal plasma cells in high-risk smoldering and symptomatic multiple myeloma patients

Leukemia

Volumn 26, Issue 8, 2012, Pages 1862-1869

  Paiva, B ^a,b   Gutierrez N C ^a,b   Chen, X ^b   Vidriales M B ^a,b   Montalban M A ^c   Rosiol L ^d   Oriol, A ^e   Martinez Lopez J ^c   Mateos, M V ^a,b   Lopez Corral L ^a,b   Diaz Rodriguez E ^b   Perez J J ^a,b   Fernandez Redondo E ^c   De Arriba, F ^f   Palomera, L ^g   Bengoechea, E ^h   Terol, M J ⁱ   De Paz, R ^j   Martin, A ^k   Hernandez J ^l   Orfao, A ^b,m   Lahuerta, J J ^c   Blade J ^d   Pandiella, A ^b   Miguel, J F S ^a,b   more..

^a HOSPITAL UNIVERSITARIO DE SALAMANCA   (Spain)

^b Centro de Investigacion del Cancer   (Spain)

^c HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

^d HOSPITAL CLÍNIC   (Spain)

^e HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

^f HOSPITAL MORALES MESEGUER   (Spain)

^g HOSPITAL CLÍNICO UNIVERSITARIO LOZANO BLESA   (Spain)

^h HOSPITAL DONOSTIA   (Spain)

ⁱ HOSPITAL CLÍNICO UNIVERSITARIO   (Spain)

^j HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

^k HOSPITAL VIRGEN DE LA CONCHA   (Spain)

^l HOSPITAL GENERAL DE SEGOVIA   (Spain)

^m UNIVERSITY OF SALAMANCA   (Spain)

more..

Author keywords

CD81; flow cytometry; multiple myeloma; phenotype; plasma cells; survival

Indexed keywords

CD81 PROTEIN; TUMOR PROTEIN; UNCLASSIFIED DRUG;

AGED; ARTICLE; CANCER PROGNOSIS; DISEASE COURSE; FLOW CYTOMETRY; HIGH RISK PATIENT; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; MULTIPLE MYELOMA; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PLASMA CELL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION;

EID: 84864880920     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2012.42     Document Type: Article

References (40)

1. Gutierrez NC, Castellanos MV, Martin ML, Mateos MV, Hernandez JM, Fernandez M et al. Prognostic and biological implications of genetic abnormalities in multiple myeloma undergoing autologous stem cell transplantation: t(4;14) is the most relevant adverse prognostic factor, whereas RB deletion as a unique abnormality is not associated with adverse prognosis. Leukemia 2007; 21: 143-150.
2. Gutierrez NC, Garcia JL, Hernandez JM, Lumbreras E, Castellanos M, Rasillo A et al. Prognostic and biologic significance of chromosomal imbalances assessed by comparative genomic hybridization in multiple myeloma. Blood 2004; 104: 2661-2666.
3. Avet-Loiseau H, Attal M, Moreau P, Charbonnel C, Garban F, Hulin C et al. Genetic abnormalities and survival in multiple myeloma: the experience of the Intergroupe Francophone du Myélome. Blood 2007; 109: 3489-3495.
4. Shaughnessy Jr JD, Zhan F, Burington BE, Huang Y, Colla S, Hanamura I et al. A validated gene expression model of high-risk multiple myeloma is defined by deregulated expression of genes mapping to chromosome 1. Blood 2007; 109: 2276-2284.
5. Mateo G, Montalban MA, Vidriales MB, Lahuerta JJ, Mateos MV, Gutierrez N et al. Prognostic value of immunophenotyping in multiple myeloma: a study by the PETHEMA/GEM cooperative study groups on patients uniformly treated with high-dose therapy. J Clin Oncol 2008; 26: 2737-2744.
6. Bahlis NJ, King AM, Kolonias D, Carlson LM, Liu HY, Hussein MA et al. CD28-mediated regulation of multiple myeloma cell proliferation and survival. Blood 2007; 109: 5002-5010.
7. Bataille R, Jego G, Robillard N, Barille-Nion S, Harousseau JL, Moreau P et al. The phenotype of normal, reactive and malignant plasma cells. Identification of "many and multiple myelomas" and of new targets for myeloma therapy. Haematologica 2006; 91: 1234-1240.
8. Tedder TF, Inaoki M, Sato S. The CD19-CD21 complex regulates signal transduction thresholds governing humoral immunity and autoimmunity. Immunity 1997; 6: 107-118.
9. Cherukuri A, Carter RH, Brooks S, Bornmann W, Finn R, Dowd CS et al. B cell signaling is regulated by induced palmitoylation of CD81. J Biol Chem 2004; 279: 31973-31982.
10. Cherukuri A, Shoham T, Sohn HW, Levy S, Brooks S, Carter R et al. The tetraspanin CD81 is necessary for partitioning of coligated CD19/CD21-B cell antigen receptor complexes into signaling-active lipid rafts. J Immunol 2004; 172: 370-380.
11. Shoham T, Rajapaksa R, Boucheix C, Rubinstein E, Poe JC, Tedder TF et al. The tetraspanin CD81 regulates the expression of CD19 during B cell development in a postendoplasmic reticulum compartment. J Immunol 2003; 171: 4062-4072.
12. van Zelm MC, Smet J, Adams B, Mascart F, Schandene L, Janssen F et al. CD81 gene defect in humans disrupts CD19 complex formation and leads to antibody deficiency. J Clin Invest 2010; 120: 1265-1274.
13. Barrena S, Almeida J, Yunta M, Lopez A, Fernandez-Mosteirin N, Giralt M et al. Aberrant expression of tetraspanin molecules in B-cell chronic lymphoproliferative disorders and its correlation with normal B-cell maturation. Leukemia 2005; 19: 1376-1383.
14. Luo RF, Zhao S, Tibshirani R, Myklebust JH, Sanyal M, Fernandez R et al. CD81 protein is expressed at high levels in normal germinal center B cells and in subtypes of human lymphomas. Hum Pathol 2009; 41: 271-280.
15. Carloni V, Mazzocca A, Ravichandran KS. Tetraspanin CD81 is linked to ERK/MAPKinase signaling by Shc in liver tumor cells. Oncogene 2004; 23: 1566-1574.
16. Mateos MV, Oriol A, Martinez-Lopez J, Gutierrez N, Teruel AI, de Paz R et al. Bortezomib, melphalan, and prednisone versus bortezomib, thalidomide, and prednisone as induction therapy followed by maintenance treatment with bortezomib and thalidomide versus bortezomib and prednisone in elderly patients with untreated multiple myeloma: a randomised trial. Lancet Oncol 2010; 11: 934-941.
17. Blade J, Samson D, Reece D, Apperley J, Bjorkstrand B, Gahrton G et al. Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Myeloma Subcommittee of the EBMT. European Group for Blood and Marrow Transplant. BrJHaematol 1998; 102: 1115-1123.
18. International Myeloma Working Group. Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group. Br J Haematol 2003; 121: 749-757.
19. Paiva B, Martinez-Lopez J, Vidriales M, Mateos M, Montalban M, Fernandez-Redondo E et al. Comparison of immunofixation, serum free light chain, and immunophenotyping for response evaluation and prognostication in multiple myeloma. J Clin Oncol 2011; 29: 1627-1633.
20. Mateo Manzanera G, San Miguel Izquierdo J, Orfao de Matos A. Immunophenotyping of plasma cells in multiple myeloma. Methods Mol Med 2005; 113: 5-24.
21. Fonseca R, Bergsagel PL, Drach J, Shaughnessy J, Gutierrez N, Stewart K et al. International Myeloma Working Group molecular classification of multiple myeloma: spotlight review. Leukemia 2009; 23: 2210-2221.
22. Gutierrez NC, Sarasquete ME, Misiewicz-Krzeminska I, Delgado M, De Las Rivas J, Ticona FV et al. Deregulation of microRNA expression in the different genetic subtypes of multiple myeloma and correlation with gene expression profiling. Leukemia 2010; 24: 629-637.
23. Esparís-Ogando A, Alegre A, Aguado B, Mateo G, Gutiérrez N, Bladé J et al. Bortezomib is an efficient agent in plasma cell leukemias. Int J Cancer 2005; 114: 665-667.
24. Greipp PR, San MJ, Durie BG, Crowley JJ, Barlogie B, Blade J et al. International Staging System for multiple myeloma. J Clin Oncol 2005; 23: 3412-3420.
25. Avet-Loiseau H, Li C, Magrangeas F, Gouraud W, Charbonnel C, Harousseau J et al. Prognostic significance of copy-number alterations in multiple myeloma. J Clin Oncol 2009; 27: 4585-4590.
26. Fonseca R, Blood E, Rue M, Harrington D, Oken MM, Kyle RA et al. Clinical and biologic implications of recurrent genomic aberrations in myeloma. Blood 2003; 101: 4569-4575.
27. Zhan F, Huang Y, Colla S, Stewart J, Hanamura I, Gupta S et al. The molecular classification of multiple myeloma. Blood 2006; 108: 2020-2028.
28. Broyl A, Hose D, Lokhorst H, de Knegt Y, Peeters J, Jauch A et al. Gene expression profiling for molecular classification of multiple myeloma in newly diagnosed patients. Blood 2010; 116: 2543-2553.
29. Walker B, Wardell C, Chiecchio L, Smith E, Boyd K, Neri A et al. Aberrant global methylation patterns affect the molecular pathogenesis and prognosis of multiple myeloma. Blood 2011; 117: 553-562.
30. Mateo G, Castellanos M, Rasillo A, Gutierrez NC, Montalban MA, Martin ML et al. Genetic abnormalities and patterns of antigenic expression in multiple myeloma. Clin Cancer Res 2005; 11: 3661-3667.
31. Crespo M, Bosch F, Villamor N, Bellosillo B, Colomer D, Rozman M et al. ZAP-70 expression as a surrogate for immunoglobulin-variable-region mutations in chronic lymphocytic leukemia. N Engl J Med 2003; 348: 1764-1775.
32. Schroers R, Griesinger F, Trümper L, Haase D, Kulle B, Klein-Hitpass L et al. Combined analysis of ZAP-70 and CD38 expression as a predictor of disease progression in B-cell chronic lymphocytic leukemia. Leukemia 2005; 19: 750-758.
33. Kyle RA, Rajkumar SV. Criteria for diagnosis, staging, risk stratification and response assessment of multiple myeloma. Leukemia 2009; 23: 3-9.
34. Maecker H, Levy S. Normal lymphocyte development but delayed humoral immune response in CD81-null mice. J Exp Med 1997; 185: 1505-1510.
35. Miyazaki T, Mü ller U, Campbell K. Normal development but differentially altered proliferative responses of lymphocytes in mice lacking CD81. EMBO J 1997; 16: 4217-4225.
36. Tsitsikov E, Gutierrez-Ramos J, Geha R. Impaired CD19 expression and signaling, enhanced antibody response to type II T independent antigen and reduction of B-1 cells in CD81-deficient mice. Proc Natl Acad Sci USA 1997; 94: 10844-10849.
37. Shoham T, Rajapaksa R, Kuo C, Haimovich J, Levy S. Building of the tetraspanin web: distinct structural domains of CD81 function in different cellular compartments. Mol Cell Biol 2006; 26: 1373-1385.
38. Perez-Persona E, Vidriales MB, Mateo G, Garcia-Sanz R, Mateos MV, de Coca AG et al. New criteria to identify risk of progression in monoclonal gammopathy of uncertain significance and smoldering multiple myeloma based on multiparameter flow cytometry analysis of bone marrow plasma cells. Blood 2007; 110: 2586-2592.
39. Kyle R, Remstein E, Therneau T, Dispenzieri A, Kurtin P, Hodnefield J et al. Clinical course and prognosis of smoldering (asymptomatic) multiple myeloma. N Engl J Med 2007; 356: 2582-2590.
40. Korde N, Kristinsson S, Landgren O. Monoclonal gammopathy of undetermined significance (MGUS) and smoldering multiple myeloma (SMM): novel biological insights and development of early treatment strategies. Blood 2011; 117: 5573-5581.